Infective Agents Institute, Croix rousse Hospital
Lyon, Rhone, 69004, France
Location status: Recruiting
NCT Number: NCT07805590
Respiratory viruses circulate throughout the year, and particularly during the winter. Consequently, co-infections involving two or more viruses can occur. The study of virus-virus interactions at the population level is necessary to understand the dynamics of co-infections. Viruses such as IAV (influenza A virus) and rhinoviruses (common cold viruses) are known to have a negative interaction, mutually excluding one another, which results in a reduced likelihood of co-infection. The study of virus-virus interactions at the population level constitutes an essential first step towards understanding and characterising these phenomena at the individual level, and subsequently at the cellular level. Using integrative approaches combining epidemiological data, clinical observations and in vitro models, it has been shown that IAV and SARS-CoV-2 have a negative interaction, whilst potentially contributing to the severity of respiratory infections. This research also suggests that prior vaccination against IAV reduces the risk of severe forms of the disease.
Furthermore, viral co-infections appear to influence the severity of respiratory infections, particularly in children. Children appear to be more susceptible to these co-infections, with around 35% of cases reported, compared with 6% in adults. In this context, the study and characterisation of virus-virus interactions appear essential to better understand the pathophysiology of respiratory infections and improve the management of co-infected patients.
Every week, Dr Jean-Sébastien Casalegno publishes the Hospices Civils' epidemiological bulletin, which considers the prevalence of respiratory viruses detected at the Centre de Biologie et Pathologie Nord. This local dataset reports on the co-circulation of respiratory viruses and is of interest for the study of virus-virus interactions at a population level.
The impact of viral co-infections on the severity of respiratory infections remains a subject of debate in the literature. Understanding the dynamics of interaction between respiratory viruses at a population level, in order to identify preferential associations or exclusions, is essential for assessing the clinical impact of co-infections.
Interested in participating?
Request InfoAll sexes
Observational
Lyon, Rhone, 69004, France
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Virologic results for biological samples collected as part of the diagnosis of respiratory viral infections in patients of all ages receiving routine care, regardless of their department of origin, during the winter periods from 2022 to 2025.
Time frame: Baseline
To characterize virus-virus interactions from 2022 to 2025 by assessing a co-infection exclusion score in order to identify, based on PCR results from respiratory samples collected over specific time periods (months/years), the preferred (positive) associations and exclusion (negative) relationships between respiratory viruses.
Time frame: Baseline
Frequency of virologically confirmed co-infections, defined as the proportion of participants with a positive RT-PCR test for at least two respiratory viruses.
Time frame: Baseline
Description of the weekly circulation of respiratory viruses over the study period.
Time frame: Baseline
Proportion of respiratory viruses detected among all samples taken during the study period, regardless of the PCR result.
Hospices Civils de Lyon
Other
Acronym: INTERVI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07156890
Respiratory Viruses
Rotterdam, South Holland, Netherlands
View Trial DetailsNCT07287137
COVID - 19, COVID -19
Bethesda, Maryland, United States
View Trial DetailsNCT07001904
Disease Severity, Interleukin-6
Tanta, El-Gharbia, Egypt
View Trial DetailsNCT06041126
Chronic Disease, Chronic Obstructive Pulmonary Disease
Balıkesir, Turkey (Türkiye)
View Trial Details